Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• A Korean patient with Guillain-Barré syndrome following acute hepatitis E whose cholestasis resolved with steroid therapy.1 passage
• A case of Alagille syndrome presenting with chronic cholestasis in an adult.1 passage
• A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult.1 passage
• A case of levocetirizine-induced liver injury.1 passage
• A case of portal hypertension by presumed as plexiform neurofibroma at the hepatic hilum.1 passage
• A case of primary hepatic actinomycosis: an enigmatic inflammatory lesion of the liver.1 passage
• A case of ruptured hepatic angiomyolipoma in a young male.1 passage
• A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.1 passage
• A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016.1 passage
• A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.1 passage
• A lexicon for hepatocellular carcinoma surveillance ultrasonography: benign versus malignant lesions.1 passage
• A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea.1 passage
• Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis.1 passage
• Acute kidney injury in liver cirrhosis: new definition and application.1 passage
• Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C.1 passage
• Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding.1 passage
• Acute-on-chronic liver failure: A predictor of poor prognosis in patients with variceal bleeding or a risk factor for variceal bleeding?1 passage
• Acute-on-chronic liver failure: a new syndrome in cirrhosis.1 passage
• Adefovir-induced Fanconi syndrome associated with osteomalacia.1 passage
• Advances in ultrasound diagnosis in chronic liver diseases.1 passage
• Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma.1 passage
• Alcohol and hepatocarcinogenesis.1 passage
• Alcohol associated liver cirrhotics have higher mortality after index hospitalization: Long-term data of 5,138 patients.1 passage
• Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume.1 passage
• An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.1 passage
• Anti-fibrotic treatments for chronic liver diseases: The present and the future.1 passage
• Anticoagulation in cirrhosis: a new paradigm?1 passage
• Application of transient elastography in nonalcoholic fatty liver disease.1 passage
• Approaches to quantifying Hepatitis B Virus covalently closed circular (ccc)DNA.1 passage
• Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?1 passage
• Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?1 passage
• Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B.1 passage
• Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study.1 passage
• Association between serum TNF-α and sarcopenia in liver cirrhosis.1 passage
• Autophagy and liver cancer.1 passage
• Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.1 passage
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.1 passage
• Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma.1 passage
• Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.1 passage
• Bilateral optic neuropathy related to severe anemia in a patient with alcoholic cirrhosis: a case report and review of the literature.1 passage
• Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C.1 passage
• Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma.1 passage
• Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis.1 passage
• Caroli's disease misdiagnosed as intraductal papillary neoplasm of the bile duct.1 passage
• Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis.1 passage
• Changes in the epidemiology and management of bacterial infections in cirrhosis.1 passage
• Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases.1 passage
• Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years.1 passage
• Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.1 passage
• Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion.1 passage
• Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.1 passage
• Clinical implications of advances in liver regeneration.1 passage
• Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea.1 passage
• Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma.1 passage
• Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis.1 passage
• Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease.1 passage
• Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.1 passage
• Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.1 passage
• Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005-2012.1 passage
• Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.1 passage
• Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop.1 passage
• Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma.1 passage
• Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update.1 passage
• Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion.1 passage
• Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.1 passage
• Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.1 passage
• Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.1 passage
• Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: case report with 8-year follow up.1 passage
• Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review.1 passage
• Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.1 passage
• Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system.1 passage
• Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea.1 passage
• Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma.1 passage
• Current and future strategies for the treatment of chronic hepatitis C.1 passage
• Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea.1 passage
• Current knowledge about biomarkers of acute kidney injury in liver cirrhosis.1 passage
• Current status and strategies for hepatitis B control in Korea.1 passage
• Current status and strategies for the control of viral hepatitis A in Korea.1 passage
• Current status and strategies for viral hepatitis control in Korea.1 passage
• Current status of and strategies for hepatitis C control in South Korea.1 passage
• Current status of laparoscopic liver resection for hepatocellular carcinoma.1 passage
• Current understanding of primary biliary cholangitis.1 passage
• Cyanoacrylate injection versus band ligation for bleeding from cardiac varices along the lesser curvature of the stomach.1 passage
• Decreased C-reactive protein induces abnormal vascular structure in a rat model of liver dysfunction induced by bile duct ligation.1 passage
• Detect or not to detect very early stage hepatocellular carcinoma? The western perspective.1 passage
• Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C.1 passage
• Development of autoimmune hepatitis in a psoriasis patient without immunosuppressive therapy.1 passage
• Direct comparison of biopsy techniques for hepatic malignancies.1 passage
• Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?1 passage
• Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.1 passage
• Discussion on critical points for a tailored therapy to cure hepatitis C virus infection.1 passage
• Drug induced liver injury: East versus West - a systematic review and meta-analysis.1 passage
• Drug-induced liver injury caused by iodine-131.1 passage
• Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them.1 passage
• Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.1 passage
• Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.1 passage
• Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes.1 passage
• Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebo-controlled trial.1 passage
• Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.1 passage
• Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.1 passage
• Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.1 passage
• Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study.1 passage
• Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.1 passage
• Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.1 passage
• Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.1 passage
• Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.1 passage
• Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).1 passage
• Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.1 passage
• Emergency endoscopic variceal ligation in cirrhotic patients with blood clots in the stomach but no active bleeding or stigmata increases the risk of rebleeding.1 passage
• Emerging medical therapies for severe alcoholic hepatitis.1 passage
• Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases.1 passage
• Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis.1 passage
• Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.1 passage
• Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.1 passage
• Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.1 passage
• Epidemiology of alcoholic liver disease in Korea.1 passage
• Epidemiology of liver cancer in South Korea.1 passage
• Epithelioid angiomyolipoma of the liver: a case report.1 passage
• Erectile dysfunction in patients with liver disease related to chronic hepatitis B.1 passage
• Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.1 passage
• Evaluation of bioenergetic and mitochondrial function in liver transplantation.1 passage
• Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH.1 passage
• Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals.1 passage
• Extrahepatic manifestations of hepatitis E virus: An overview.1 passage
• Fatigue and weakness hinder patient social reintegration after liver transplantation.1 passage
• Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B.1 passage
• Fecal microbiota transplantation in alcohol related liver diseases.1 passage
• Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma.1 passage
• From intestinal dysbiosis to alcohol-associated liver disease.1 passage
• From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?1 passage
• Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.1 passage
• Genetic predisposition in nonalcoholic fatty liver disease.1 passage
• Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies.1 passage
• Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.1 passage
• Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease.1 passage
• Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.1 passage
• Hepatic perivascular epithelioid cell tumor (PEComa): a case report with a review of literatures.1 passage
• Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand.1 passage
• Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.1 passage
• Hepatitis C virus-induced hepatocellular carcinoma.1 passage
• Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?1 passage
• Hepatogastric fistula as a rare complication of pyogenic liver abscess.1 passage
• Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.1 passage
• Histopathological evaluation of liver fibrosis and cirrhosis regression.1 passage
• Histopathology of a benign bile duct lesion in the liver: Morphologic mimicker or precursor of intrahepatic cholangiocarcinoma.1 passage
• Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification.1 passage
• Imaging findings for intravascular large B-cell lymphoma of the liver.1 passage
• Imaging findings of mimickers of hepatocellular carcinoma.1 passage
• Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation.1 passage
• Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection.1 passage
• Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma.1 passage
• Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma.1 passage
• Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study.1 passage
• Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients.1 passage
• Incidence and risk factors of dysphagia after variceal band ligation.1 passage
• Influence of P53 on the radiotherapy response of hepatocellular carcinoma.1 passage
• Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.1 passage
• Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients.1 passage
• Influence of ultrasound contrast agents on spectral Doppler analysis in recipients of liver transplantation.1 passage
• Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway.1 passage
• Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis.1 passage
• Inter-professional and inter-departmental alcoholism rehabilitation program.1 passage
• Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling.1 passage
• Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein.1 passage
• Is scheduled second chemoembolization necessary for early stage hepatocellular carcinoma showing complete response after first chemoembolization?1 passage
• Journal metrics of Clinical and Molecular Hepatology based on the Web of Science Core Collection.1 passage
• Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis.1 passage
• Life-sustaining treatment and palliative care in patients with liver cirrhosis - legal, ethical, and practical issues.1 passage
• Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease.1 passage
• Liver dysfunction induced by systemic hypersensitivity reaction to lamotrigine: case report.1 passage
• Liver graft from donation after circulatory death donor: Real practice to improve graft viability.1 passage
• Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm.1 passage
• Liver metastasis of meningeal hemangiopericytoma: a study of 5 cases.1 passage
• Liver transplantation for advanced hepatocellular carcinoma.1 passage
• Liver-lung axes in alcohol-related liver disease.1 passage
• Living-donor liver transplantation for giant hepatic hemangioma with diffuse hemangiomatosis in an adult: a case report.1 passage
• Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease.1 passage
• Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.1 passage
• Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.1 passage
• Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.1 passage
• Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir.1 passage
• MAFLD Enhances Clinical Practice for Liver Disease in the Asia-Pacific region.1 passage
• Magnetization-tagged MRI is a simple method for predicting liver fibrosis.1 passage
• Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend.1 passage
• Management of direct antiviral agent failures.1 passage
• Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals.1 passage
• Managing alcoholic liver disease.1 passage
• Managing liver cirrhotic complications: Overview of esophageal and gastric varices.1 passage
• Meta-analysis of the correlation between the rs17401966 polymorphism in kinesin family member 1B and susceptibility to hepatitis B virus related hepatocellular carcinoma.1 passage
• Metastatic endophthalmitis and thyroid abscess complicating1 passage
• Microbiota, a key player in alcoholic liver disease.1 passage
• Microwave thermosphere versus radiofrequency ablation for hepatocellular carcinoma: Are we approaching the time to end the debate?1 passage
• More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis.1 passage
• Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.1 passage
• NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.1 passage
• Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.1 passage
• New next-generation microwave thermosphere ablation for small hepatocellular carcinoma.1 passage
• New perspectives of biomarkers for the management of chronic hepatitis B.1 passage
• New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.1 passage
• Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase.1 passage
• Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.1 passage
• Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights.1 passage
• Nonalcoholic fatty liver disease and early prediction of gestational diabetes using machine learning methods.1 passage
• Novel biomarkers for the management of chronic hepatitis B.1 passage
• Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake.1 passage
• Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.1 passage
• Obesity and the risk of primary liver cancer: A systematic review and meta-analysis.1 passage
• Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects.1 passage
• Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry.1 passage
• Oxidative stress and glutamate excretion in alcoholic steatosis: Metabolic synapse between hepatocyte and stellate cell.1 passage
• Pathologic differential diagnosis of metastatic carcinoma in the liver.1 passage
• Peliosis hepatis presenting with massive hepatomegaly in a patient with idiopathic thrombocytopenic purpura.1 passage
• Percutaneous cryoablation for hepatocellular carcinoma.1 passage
• Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.1 passage
• Personalized management of cirrhosis by non-invasive tests of liver fibrosis.1 passage
• Personalized treatment of hepatitis B.1 passage
• Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis.1 passage
• Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world?1 passage
• Portal biliopathy treated with endoscopic biliary stenting.1 passage
• Portal flow steal after liver transplantation.1 passage
• Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt.1 passage
• Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology.1 passage
• Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma.1 passage
• Predictors of steroid non-response and new approaches in severe alcoholic hepatitis.1 passage
• Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.1 passage
• Preference elicitation approach for measuring the willingness to pay for liver cancer treatment in Korea.1 passage
• Prevention and management of gastroesophageal varices.1 passage
• Prevention of Hepatitis B reactivation in the setting of immunosuppression.1 passage
• Primary adenosquamous carcinoma of the liver: a case report.1 passage
• Primary squamous cell carcinoma of the liver: a case report.1 passage
• Programmed cell death in alcohol-associated liver disease.1 passage
• Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients.1 passage
• Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals.1 passage
• Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study.1 passage
• Radioembolization for the treatment of hepatocellular carcinoma.1 passage
• Radiomics and radiogenomics of primary liver cancers.1 passage
• Recent advances in nonalcoholic fatty liver disease metabolomics.1 passage
• Recent advances in the imaging of hepatocellular carcinoma.1 passage
• Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.1 passage
• Recent research trends and updates on nonalcoholic fatty liver disease.1 passage
• Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.1 passage
• Recent updates on the management of autoimmune hepatitis.1 passage
• Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban.1 passage
• Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy.1 passage
• Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis.1 passage
• Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source.1 passage
• Resection plane-dependent error in computed tomography volumetry of the right hepatic lobe in living liver donors.1 passage
• Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes.1 passage
• Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B.1 passage
• Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.1 passage
• Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis.1 passage
• Role of endoscopic treatment or balloon-occluded retrograde transvenous obliteration in patients with Child-Pugh class C end-stage liver cirrhosis and esophageal/gastric varices.1 passage
• Role of liver transplantation in severe alcoholic hepatitis.1 passage
• Roles of the complement system in alcohol-induced liver disease.1 passage
• SYSTEMATIC REVIEW WITH META-ANALYSIS: NON-ALCOHOLIC FATTY LIVER DISEASE AND THE ASSOCIATION WITH PREGNANCY OUTCOMES.1 passage
• Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization.1 passage
• Sarcopenia: Ammonia metabolism and hepatic encephalopathy.1 passage
• Scaling up the in-hospital hepatitis C virus care cascade in Taiwan.1 passage
• Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard.1 passage
• Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection.1 passage
• Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.1 passage
• Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.1 passage
• Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis.1 passage
• Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome.1 passage
• Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story.1 passage
• Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?1 passage
• Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma.1 passage
• Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.1 passage
• Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.1 passage
• Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure.1 passage
• Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial.1 passage
• Strategic application of radiotherapy for hepatocellular carcinoma.1 passage
• Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients.1 passage
• Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3cm) hepatocellular carcinoma.1 passage
• Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.1 passage
• Switching to systemic therapy after locoregional treatment failure: Definition and best timing.1 passage
• THE MANAGEMENT OF POST-TRANSPLANTATION RECURRENCE OF HEPATOCELLULAR CARCINOMA.1 passage
• Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.1 passage
• Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.1 passage
• Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.1 passage
• The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study.1 passage
• The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy.1 passage
• The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma.1 passage
• The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.1 passage
• The cost of liver disease in Korea: methodology, data, and evidence.1 passage
• The cut-off value of transient elastography to the value of hepatic venous pressure gradient in alcoholic cirrhosis.1 passage
• The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future.1 passage
• The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer?1 passage
• The effect of moderate alcohol drinking in nonalcoholic fatty liver disease.1 passage
• The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.1 passage
• The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B.1 passage
• The fibrogenic process and the unleashing of acute-on-chronic liver failure.1 passage
• The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction.1 passage
• The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.1 passage
• The lymphatic system in alcohol-associated liver disease.1 passage
• The mutational landscape of hepatocellular carcinoma.1 passage
• The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE.1 passage
• The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.1 passage
• The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: advantages and pitfalls.1 passage
• The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease.1 passage
• The use of immunosuppression in autoimmune hepatitis: A current literature review.1 passage
• The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study.1 passage
• Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.1 passage
• Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.1 passage
• Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.1 passage
• Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.1 passage
• Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis.1 passage
• Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis.1 passage
• Treatment options after sorafenib failure in patients with hepatocellular carcinoma.1 passage
• Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017.1 passage
• U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases.1 passage
• Ultraselective conventional transarterial chemoembolization: When and how?1 passage
• Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio.1 passage
• Undifferentiated embryonal sarcoma of the liver in an adult patient.1 passage
• Unmet need in chronic hepatitis B management.1 passage
• Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.1 passage
• Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.1 passage
• Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective.1 passage
• Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.1 passage
• Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.1 passage
• What we need to know when performing and interpreting US elastography.1 passage
• β-blockers in advanced cirrhosis: More friend than enemy.1 passage